Tuesday, 12 June 2012
Improved Survival in BRAF-Mutated Melanoma With Trametinib | MedIndia
Improved Survival in BRAF-Mutated Melanoma With Trametinib | MedIndia
Trametinib, a MEK inhibitor, promotes survival in advanced melanoma patients with mutations in serine–threonine protein kinase B-RAF (BRAF).
http://www.medindia.net/news/healthwatch/improved-survival-in-braf-mutated-melanoma-with-trametinib-102573-1.htm#
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment